Get to know our clinical trials

Clinical trial to evaluate safety and tolerability in participants with squamous cell carcinoma of the head and neck

THE PRIMARY OBJECTIVE OF THIS STUDY IS TO EVALUATE THE TOLERABILITY OF XEVINAPANT WHEN ADDED TO WEEKLY CRT WITH CISPLATIN IN PATIENTS WITH LOCALLY ADVANCED SCC OF THE HEAD AND NECK.

Status
In recruitment
headquarters
Madrid

Technical Summary

  • PHASE IB, OPEN-LABEL, SINGLE-GROUP STUDY OF XEVINAPANT IN COMBINATION WITH CISPLATIN AND WEEKLY MODULATED INTENSITY RADIOTHERAPY TO EVALUATE SAFETY AND TOLERABILITY IN PARTICIPANTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK, SUITABLE FOR DEFINITIVE CHEMORADIOTHERAPY
  • Code EudraCT: 2023-505796-76-00
  • Protocol number: MS202359_0025
  • Promoter: MERCK KGaA
  • Molecule/Drug: xevinapant

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Imagen de un icono azul con un fonendoscopio o estetoscopio.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial


Imagen de un icono azul de un registro en el informe médico.

Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.